Galmed pharmaceuticals provides business update and reports fourth quarter and year end 2020 financial results

Tel aviv, israel, march 18, 2021 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ("galmed" or the "company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted scd1 modulator aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or nash and fibrosis, reports financial results for the three and twelve months ended december 31, 2020.
GLMD Ratings Summary
GLMD Quant Ranking